The ResonanceDx Bulk Acoustic Resonance Sensing Platform

Moreno, Carlos S.

Title:

The ResonanceDx Bulk Acoustic Resonance Sensing Platform

dc.contributor.author	Moreno, Carlos S.
dc.contributor.corporatename	Georgia Institute of Technology. Institute for Electronics and Nanotechnology	en_US
dc.contributor.corporatename	Emory University. School of Medicine	en_US
dc.contributor.corporatename	Emory University. Department of Pathology and Laboratory Medicine	en_US
dc.date.accessioned	2020-10-27T20:22:34Z
dc.date.available	2020-10-27T20:22:34Z
dc.date.issued	2020-10-22
dc.description	Presented online October 22, 2020 from 11:00 a.m.-12:00 p.m. Fall 2020 NANOFANS Webinar Series: Session 4.	en_US
dc.description	Fall 2020 NanoFANS (Focusing on Advanced Nanobio-Systems) Forum - “Bridging Biology & Nanotechnology".	en_US
dc.description	Dr. Moreno obtained his B.S. and M.S. in Aeronautics and Astronautics from MIT, and worked for NASA before he earned his PhD in Genetics and Molecular Biology from Emory University in 1998. He is Associate Professor of Pathology & Laboratory Medicine and Biomedical Informatics at Emory University, where he is a member of the Winship Cancer Institute. He specializes in cancer bioinformatics and cancer genomics, and his laboratory has used whole genome expression analysis and next-generation sequencing to identify biomarkers of aggressive disease in prostate cancer. He is Section Editor-in-Chief of the Cancer Biomarkers section of the journal Cancers. He is a co-inventor on a patent application for a system to detect biomarkers using piezoelectric resonators. In 2017, he co-founded ResonanceDx to develop rapid, point-of-care diagnostic devices.	en_US
dc.description	Runtime: 39:19 minutes	en_US
dc.description.abstract	As the global coronavirus pandemic continues, there is an urgent clinical and epidemiological need to be able to assess whether or not someone has contracted COVID19. The ResonanceDx Bulk Acoustic Resonance Sensing (BARS) platform detects the shifts in the piezoelectric acoustic resonant frequencies that occur upon antibody-antigen binding and is approximately an order of magnitude more sensitive than standard ELISA detection methods. Moreover, this approach provides results in approximately 5 minutes with no sample processing or expensive or hard to manufacture reagents, enabling the use of whole blood or saliva. The applications for such a rapid point-of-care COVID19 diagnostic test are numerous, including identifying exposed healthcare workers, safely facilitating regular procedures from dental visits to elective surgery, allowing family members to visit hospitals or nursing homes, allowing non-essential workers to return to work, college students to campus, safe travel on airlines or cruises, or admission to large gatherings for members of the general public.	en_US
dc.format.extent	39:19 minutes
dc.identifier.uri	http://hdl.handle.net/1853/63804
dc.language.iso	en_US	en_US
dc.publisher	Georgia Institute of Technology	en_US
dc.relation.ispartofseries	NanoFANS Forum
dc.subject	COVID-19	en_US
dc.subject	Point of care diagnostics	en_US
dc.subject	SARS-CoV-2	en_US
dc.title	The ResonanceDx Bulk Acoustic Resonance Sensing Platform	en_US
dc.type	Moving Image
dc.type.genre	Lecture
dspace.entity.type	Publication
local.contributor.corporatename	Institute for Electronics and Nanotechnology (IEN)
local.relation.ispartofseries	NanoFANS Forum
relation.isOrgUnitOfPublication	5d316582-08fe-42e1-82e3-9f3b79dd6dae
relation.isSeriesOfPublication	305b1e69-4bca-401d-9f07-8343ad74d343